Floatz logo

Memantine

Cognitive Disorder

UNC Lineberger Comprehensive Cancer CenterSmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
81/ 100

Competitive context

132 Active assets in the Cognitive Disorder cohort.

Asset / SponsorPhaseRating
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
LEVODOPA
Vanderbilt University Medical Center
Phase 4BB
Metformin
Fudan University
Phase 4BB
QUETIAPINE
Emory University
Phase 4BB

View all 50 →

Same molecule, other indications

Memantine is also rated in:

Alzheimer diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
Lewy body dementiaDormant
BBB
Indicative · Phase 4
72 / 100
View asset →
dementiaDormant
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →